Product Description
Mechanisms of Action: ERBB2 Inhibitor,ERBB3 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merrimack
Company Location: CAMBRIDGE MA 02142
Company CEO: Gary L. Crocker
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Esophageal Cancer|Gastrointestinal Cancer
Phase 1: Oncology Solid Tumor Unspecified|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MM-111-13-02-04 | P2 |
Terminated |
Gastrointestinal Cancer|Esophageal Cancer |
2015-07-01 |
|
| Open Label MM-111 in patients with HER2 | P2 |
Terminated |
Esophageal Cancer |
2015-05-29 |
|
| MM-111-01-01-03 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2014-04-01 |
|
| MM-111-02-12-02 | P1 |
Completed |
Breast Cancer |
2013-07-01 |